Staderini, MatteoAulić, SuzanaBartolini, ManuelaTran, Hoang Ngoc AiGonzález-Ruiz, VíctorPérez, Daniel I.Martínez Gil, AnaAndrisano, VincenzaLegname, GiuseppeMenéndez Ramos, José CarlosBolognesi, Maria LauraCabezas Baudot, NievesMartín Carmona, María Antonia2024-02-072024-02-072013-01-03Staderini M, Aulić S, Bartolini M, Tran HNA, González-Ruiz V, Pérez DI, et al. A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer’s and Prion Diseases. ACS Med Chem Lett 2013;4:225–9. https://doi.org/10.1021/ml3003601948-587510.1021/ml3003605https://hdl.handle.net/20.500.14352/99813(E)-6-Methyl-4′-amino-2-styrylquinoline (3) is a small molecule with the proper features to potentially diagnose, deliver therapy and monitor response to therapy in protein misfolding diseases. These features include compound fluorescent emission in the NIR region and its ability to interact with both Aβ and prion fibrils, staining them with high selectivity. Styrylquinoline 3 also inhibits Aβ self-aggregation in vitro and prion replication in the submicromolar range in a cellular context. Furthermore, it is not toxic and is able to cross the blood brain barrier in vitro (PAMPA test).engjournal articlehttps://doi.org/10.1021/ml3003605restricted accessAggregationprotein misfolding diseasesamyloidfibrillation inhibitorsQuímica analítica (Farmacia)2301 Química Analítica